Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 9/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109189 | 0.83 | KDR (0.49) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL6593493 | 0.82 | KDR (0.53) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL6596354 | 0.80 | CDK2 (0.53) | KDRPTK2AKT1PLK1CDK2 | |
| SCHEMBL5102123 | 0.80 | CDK2 (0.71) | CDK2CDK4 | |
| SCHEMBL5108570 | 0.79 | KDR (0.50) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL5095453 | 0.78 | KDR (0.48) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL5105343 | 0.76 | CDK2 (0.69) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL5102825 | 0.76 | CDK2 (0.73) | CDK2CDK4 | |
| SCHEMBL5102233 | 0.75 | KDR (0.46) | KDRPTK2PLK1CDK2GSK3B | |
| SCHEMBL4826055 | 0.74 | CDK2 (0.47) | KDRPTK2PLK1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442697-B2 | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | MOTOROLA MOBILITY LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074096-A1 | 4-Imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity | CCNI, CDK3, CDK4 | KDR 821/4885PTK2 1742/4885AKT1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.